Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: Two Treatments Progress As Moderna/Takeda Investigation Concludes

Executive Summary

Takeda and Moderna have identified the source of metallic particles in some lots of mRNA-1273 in Japan, but believe the two deaths identified to be coincidental. Pfizer starts protease inhibitor trial, and Rigel reports fostamatinib data. 

You may also be interested in...



Stock Watch: How The Pandemic Impact On Pharma’s Value Chain Is Mutating

From clinical trials to in-person sales calls, the pharmaceutical value chain has been tested by the COVID-19 pandemic, but has held up. Nevertheless, recent friction within this chain may be more than a passing irritation.

Coronavirus Update: Another Post-Moderna Vaccine Death Reported In Japan

A third death has been reported in Japan following dosing with Moderna's mRNA vaccine and while an investigation is underway, it is not seen as product-related. Takeda has also signed a production and supply deal with Japan's government for Novavax's nanoparticle vaccine. 

Coronavirus Update: Japan Probes Deaths After Moderna Vaccine

Government and companies conducting urgent investigation into two deaths in recipients of Moderna vaccine, the causes of which remain unclear at this stage.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145001

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel